Development and manufacture of lentiviral vectors

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberCPMP/BWP/2458/03
Effective from01/11/2005
KeywordsGene therapy medicinal product, lentiviral vector, quality, manufacturing, advanced therapy medicinal products (ATMPs), lentivirus, development
DescriptionThis guideline describes quality aspects that are relevant for lentiviral vectors (LV). It applies to LV intended for ex vivo or in vivo application.

Related content

How helpful is this page?

Average rating:

 Based on 25 ratings

Add your rating:

See all ratings
5 ratings
5 ratings
5 ratings
5 ratings
5 ratings

Tell us more